• Publications
  • Influence
A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes.
We performed a multitiered, case-control association study of psoriasis in three independent sample sets of white North American individuals (1,446 cases and 1,432 controls) with 25,215 genecentricExpand
  • 1,023
  • 37
Psoriasis: epidemiology, clinical features, and quality of life
Psoriasis is a common chronic, recurrent, immune mediated disease of the skin and joints. It can have a significant negative impact on the physical, emotional, and, psychosocial wellbeing of affectedExpand
  • 671
  • 34
  • PDF
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
To gain further insight into the genetic architecture of psoriasis, we conducted a meta-analysis of 3 genome-wide association studies (GWAS) and 2 independent data sets genotyped on the Immunochip,Expand
  • 539
  • 26
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a
OBJECTIVE To assess the efficacy and safety of golimumab in patients with active psoriatic arthritis (PsA). METHODS Adult patients with PsA who had at least 3 swollen and 3 tender joints and activeExpand
  • 515
  • 25
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis.
Psoriasis is a common inflammatory disorder of the skin and other organs. We have determined that mutations in CARD14, encoding a nuclear factor of kappa light chain enhancer in B cells (NF-kB)Expand
  • 250
  • 24
Genomewide Scan Reveals Association of Psoriasis with IL-23 and NF-κB Pathways
Psoriasis is a common immune-mediated disorder that affects the skin, nails and joints. To identify psoriasis susceptibility loci, we genotyped 438,670 SNPs in 1,409 psoriasis cases and 1,436Expand
  • 951
  • 22
  • PDF
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
OBJECTIVES To evaluate further in a phase III, double blind trial the efficacy of infliximab in patients with active psoriatic arthritis (PsA), as observed in the smaller IMPACT trial. METHODS 200Expand
  • 623
  • 21
  • PDF
Psoriasis assessment tools in clinical trials
In clinical practice, broad global assessments of psoriasis disease activity and its effect on patients’ quality of life are used to assess the severity of patients’ disease and their response toExpand
  • 395
  • 16
  • PDF
Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.
BACKGROUND Psoriatic plaques are characterized by infiltration with CD4+ CD45RO+ and CD8+ CD45RO+ memory effector T lymphocytes. The recombinant protein alefacept binds to CD2 on memory effector TExpand
  • 583
  • 14